

First Survey of Metallo- β -Lactamase Producers in Clinical Isolates of *Pseudomonas aeruginosa* From a Referral Burn Center in Kurdistan Province

Enayatollah Kalantar ^{1*}, Vahideh Torabi ², Heiman Salimizand ³, Fariborz Soheili ⁴, Soheila Beiranvand ⁵, Mohammad Mehdi Soltan Dallal ⁶

¹ Environmental Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, IR Iran

² Department of Biological Sciences, Islamic Azad University, Sciences Research Branch, Tehran, IR Iran

³ Department of Microbiology, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran

⁴ School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran

⁵ Qods Hospital, Kurdistan University of Medical Sciences, Sanandaj, IR Iran

⁶ Division of Microbiology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran

ARTICLE INFO

Article type:
Original Article

Article history:
Received: 2 Nov 2011
Revised: 25 Nov 2011
Accepted: 5 Dec 2011

Keywords:
Burn Patients
P. aeruginosa
Metallo- β -lactamase
Imipenem Resistance

ABSTRACT

Background: Treatment of infectious diseases is becoming more challenging with each passing year. This is especially true for infections caused by *Pseudomonas aeruginosa*, an opportunistic pathogen with the ability to rapidly develop resistance to multiple classes of antibiotics.

Objective: This study was conducted to determine the prevalence of metallo- β -lactamase (MBL)-producing strains among multidrug-resistant *P. aeruginosa* strains isolated from burn patients.

Materials and Methods: The isolates were identified, tested for susceptibility to various antimicrobial agents, and screened for the presence of MBLs by using the double-disk synergy test. The minimal inhibitory concentration of imipenem was determined by microplate broth dilution method on Mueller-Hinton agar. To detect VIM, SIM, and GIM MBLs, the isolates were subjected to polymerase chain reaction.

Results: In this study, we identified 100 *P. aeruginosa* isolates from 176 clinical specimens obtained from burn patients. The isolates showed maximum resistance to ampicillin (100%), ceftazidime (94%), and ceftriaxone (89%). The CLSI-MBL phenotypic test showed that of the 100 *P. aeruginosa* isolates, 22 (22%) were positive for MBL production in the double-disk synergy test. Of the 22 MBL-positive *P. aeruginosa* isolates, 8 were resistant to imipenem. PCR analysis showed that 8 isolates were positive for blaVIM1. The other genes blaSIM1 and blaGIM1 were not detected.

Conclusion: The study results demonstrate the serious therapeutic threat of the spread of MBL producers among *P. aeruginosa* populations. Metallo- β -lactamases were detected in 22% of imipenem-resistant *P. aeruginosa* isolates. Early detection and infection-control practices are the best antimicrobial strategies for this organism; therefore, systematic surveillance to detect MBL producers is necessary.

Copyright ©2012 DocS.

► Implication for health policy/practice/research/medical education:

Pseudomonas aeruginosa, has showed up as a significant nosocomial pathogen particularly among burn patients. We have very scant information about the current state of *Pseudomonas aeruginosa* infections and their resistance pattern particularly ESBL. Moreover, with the increased use of prophylactic antibiotics to burn patients, careful surveillance of the changing trend of bacterial organisms and their antibiotic resistance pattern among neonates is warranted.

* Corresponding author: Dr. Enayatollah Kalantar, Environmental Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, IR Iran. Tel.: +98-8716131409, Fax: +98-8716664654, E-mail: ekalantar@hotmail.com
Copyright ©2012 DocS.

► Please cite this paper as:

Kalantari E, Torabi V, Salimizand H, Soheili F, Beiranvand S, Soltan Dallal MM, First Survey of Metallo- β -Lactamase Producers in Clinical Isolates of *Pseudomonas aeruginosa* From a Referral Burn Center in Kurdistan Province. *Jundishapur J Nat Pharm Prod.* 2012;7(1):23-6.

1. Background

Pseudomonas aeruginosa, a versatile pathogen associated with a broad spectrum of infections in humans and widely known as an opportunistic organism, is frequently involved in infections among susceptible populations, especially patients with burns (1). Furthermore, this organism possesses several virulence factors and is intrinsically resistant to most antimicrobials, a feature that is also responsible for the difficulty in treating infected patients (2). In the past decade, *P. aeruginosa* strains showing resistance to multiple β -lactam antibiotics, in particular, metallo- β -lactamase (MBL)-producing *P. aeruginosa*, have become an increasing public health problem worldwide (3-5). Furthermore, infection with MBL-producing organisms is associated with higher rates of mortality, morbidity, and health care costs (6-8).

In *P. aeruginosa*, resistance to extended-spectrum β -lactams is mediated by lack of drug penetration, which may occur due to porin mutations, efflux pumps, or hydrolysis by β -lactamases (9). On the basis of molecular studies, we can classify carbapenem-hydrolyzing enzymes into 4 groups: A, B, C, and D. The MBLs, which belong to group B, are enzymes that require divalent cations as cofactors for optimal enzyme activity and are inhibited by the action of a metal ion chelator. Hospital infections caused by *P. aeruginosa* are often difficult to eradicate because the organisms are resistant to drugs. Therefore, detection of MBL-producing *P. aeruginosa* is crucial to control the spread of resistance and for optimal treatment of patients, especially burn patients (10). There is no information concerning the prevalence of MBL-producing *P. aeruginosa* strains in Kurdistan province.

2. Objectives

We conducted this study to detect MBL-producing strains among *P. aeruginosa* isolates obtained from burn patients at Tohid hospital, which is affiliated to Kurdistan University of Medical Sciences and has a burn unit with a heavy patient turnover and extensive antibiotic use.

3. Materials and Methods

Between April 2009 and April 2010, we isolated and identified 100 strains of *P. aeruginosa* in a clinical laboratory at Tohid hospital, Sanandaj, Iran. The strains were identified as *P. aeruginosa* on the basis of colony morphology, gram staining results, motility, oxidase reaction, production of the pyocyanin pigment, nitrate reduction, the use of citrate and malonate as carbon sources, and the ability to grow at 5°C and 42°C.

3-1. Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing was done by the disk-diffusion method on Muller-Hinton agar (Merck, Germany) (11). The following antibiotics were used: amikacin, gentamicin, carbencillin, ciprofloxacin, ofloxacin, cefepime, ceftazidime, cefotaxime, ampicillin, ceftriaxone, imipenem, and meropenem.

3-2. Detection of MBL

Detection of MBL-producing *P. aeruginosa* strains was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines (11). *P. aeruginosa* ATCC 27853 was used as the negative control. For the double-disk synergy test, the inoculum was prepared after emulsifying 5-6 colonies of the suspected isolate in Mueller-Hinton broth, and the turbidity was adjusted to 0.5 McFarland opacity standard. A lawn culture was obtained on Mueller-Hinton agar, and double-disk synergy test was performed.

3-3. Determination of Minimal Inhibitory Concentration

Imipenem minimal inhibitory concentration (MIC) was determined by microplate (NUNC, Denmark) broth dilution method on Mueller-Hinton agar. Zone diameter and MIC interpretive standards for breakpoints for *P. aeruginosa* published by CLSI were used (11).

3-4 Genotypic Detection of VIM, SIM, and GIM MBL Genes by PCR

To detect VIM, SIM, and GIM MBL genes, PCR was performed for *P. aeruginosa* isolates (12)

4. Results

In this study, we identified 100 *P. aeruginosa* isolates among 176 clinical specimens obtained from patients. Table 1 shows the antibiotic-resistance pattern of *P. aeruginosa* isolates. The isolates showed maximum resistance to ampicillin (100%), ceftazidime (94%), and ceftriaxone (89%). The next step in testing was designed to identify the MBL-producing *P. aeruginosa* strains. In the CLSI-MBL phenotypic test, of the 100 *P. aeruginosa* isolates, 22 (22%) were positive for MBL production by the double-disk synergy test (Figure 1).

4-1 Determination of MIC

The MIC of MBL-positive isolates for imipenem is shown in Table 2; among 22 MBL-positive strains, 8 were resistant. PCR detection for MBL showed that 8 strains were




Figure 1. Phenotypic Detection of MBLs by DDST Among *P. aeruginosa* Isolates in Burn Patients at Tohid Hospital, Sanandaj, Iran




Figure 2. PCR for the Detection of *bla*_{VIM} Gene

Table 1. In Vitro Antibiotic Resistance Pattern of Infection-Associated *P. aeruginosa*

Antibiotic	Resistance, %
Amikacin	52
Gentamicin	54
Carbencillin	76
Ciprofloxacin	31
Ofloxacin	82
Cefepime	72
Ceftazidime	96
Cefotaxime	88
Ampicillin	100
ceftriaxone	89
Imipenem	21
Meropenem	14

positive for *bla*_{VIM1}. The other genes, *bla*_{SIM1} and *bla*_{GIM1}, were not detected (Figure 2).

5. Discussion

Because of its broad antimicrobial spectrum and stability against most common β -lactamases, imipenem generally represents one of the last alternatives for the treatment of nosocomial infections caused by multi-drug-resistant gram-negative bacteria, particularly *P. aeruginosa* (13). However, the rapid spread of MBLs among major gram-negative pathogens, particularly *P. aeruginosa*, is an emerging threat and a matter of concern worldwide (14-16); further, MBL-carrying bacteria are known to cause recalcitrant nosocomial infections (17). MBLs of the IMP, VIM, and SIM families are frequently detected in imipenem-resistant *P. aeruginosa* in Iran (18-20). In our study, a total of 100 *P. aeruginosa* strains were isolated from hospitalized burn patients in Sanandaj, Iran, in 2010, and 22% of these strains were found to be MBL producers, which is much lower than the findings from the study conducted by Mihani and Khosravi in Ahvaz

Table 2. MIC of MBL positive isolates for Imipenem

Sensitive	Intermediate	Resistant
MIC ^a , μ g / ml		
≤ 0.125	08	16
0.25		32
0.5		64
01		128 $\leq$
02		
04		
No. of <i>P. aeruginosa</i> Isolates, %		
02	01	02
02		01
04		03
02		02
03		
00		
Total of <i>P. aeruginosa</i> Isolates		
13	01	08

^a Abbreviation: MIC: Minimum Inhibitory Concentration

(18). In this study, 22% of the imipenem-resistant *P. aeruginosa* isolates were MBL-positive, with 8% positive for VIM1, which is by far the most prevalent MBL in Iran²⁰. To our knowledge, MBLs of other families like SIM have not been detected in *P. aeruginosa*. The prevalence of MBL-producing *P. aeruginosa* differs across Iranian studies, which may be because of differences in geographic regions. Further investigation is required to gain a better understanding of the epidemiology and genetic background of MBL-producing *P. aeruginosa*. The uncontrolled spread of MBL producers in hospitals may hamper treatment procedures and lead to increased morbidity and mortality. Systems for regular screening should be established

to control the spread of MBL producers, and effective infection-control programs in hospitals should be developed and implemented thoroughly. The study results demonstrate the serious therapeutic threat of the spread of MBL-producing *P. aeruginosa*. This number (22% of imipenem-resistant *P. aeruginosa*) might have been higher if other genes were included. Early detection and infection control practices are the best defense against this organism; therefore, systematic surveillance to detect MBL producers is necessary.

Acknowledgments

None declared.

Financial Disclosure

None declared.

Funding/Support

Funding for this project was provided by Vice-chancellor in Research Affairs of Kurdistan University of Medical Sciences, Sanandaj, Iran.

References

1. Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoli C, Barth A, et al. Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. *Braz J Infect Dis*. 2001;**5**(4):200-14.
2. Kerr KG, Snelling AM. *Pseudomonas aeruginosa*: a formidable and ever-present adversary. *J Hosp Infect*. 2009;**73**(4):338-44.
3. Khosravi Y, Tee Tay S, Vadivelu J. Metallo- β -lactamase-producing imipenem-resistant *Pseudomonas aeruginosa* clinical isolates in a university teaching hospital in Malaysia: detection of IMP-7 and first identification of IMP-4, VIM-2, and VIM-11. *Diagn Microbiol Infect Dis*. 2010;**67**(3):294-6.
4. Wirth FW, Picoli SU, Cantarelli VV, Goncalves AL, Brust FR, Santos LM, et al. Metallo-beta-lactamase-producing *Pseudomonas aeruginosa* in two hospitals from southern Brazil. *Braz J Infect Dis*. 2009;**13**(3):170-2.
5. Yan JJ, Hsueh PR, Ko WC, Luh KT, Tsai SH, Wu HM, et al. Metallo-beta-lactamases in clinical *Pseudomonas* isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. *Antimicrob Agents Chemother*. 2001;**45**(8):2224-8.
6. Lee K, Ha GY, Shin BM, Kim JJ, Kang JO, Jang SJ, et al. Metallo-[beta]-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: Continued prevalence of VIM-producing *Pseudomonas* spp. and increase of IMP-producing *Acinetobacter* spp. *Diagn Microbiol Infect Dis*. 2004;**50**(1):51-8.
7. Libisch B, Gacs M, Csiszar K, Muzslay M, Rokusz L, Fuzi M. Isolation of an integron-borne blaVIM-4 type metallo-beta-lactamase gene from a carbapenem-resistant *Pseudomonas aeruginosa* clinical isolate in Hungary. *Antimicrob Agents Chemother*. 2004;**48**(9):3576-8.
8. Peleg AY, Franklin C, Bell J, Spelman DW. Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia. *J Antimicrob Chemother*. 2004;**54**(3):699-700.
9. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. *Emerg Infect Dis*. 2001;**7**(2):337-41.
10. Richet HM, Mohammed J, McDonald LC, Jarvis WR. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. *Emerg Infect Dis*. 2001;**7**(2):319-22.
11. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. *Clin Lab Stand Inst*. 2010;**30**(15):10-7.
12. Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL. Detection of *Pseudomonas aeruginosa* producing metallo-beta-lactamases in a large centralized laboratory. *J Clin Microbiol*. 2005;**43**(7):3129-35.
13. Thomson JM, Bonomo RA. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril! *Curr Opin Microbiol*. 2005;**8**(5):518-24.
14. Cornaglia G, Akova M, Amicosante G, Canton R, Cauda R, Docquier JD, et al. Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. *Int J Antimicrob Agents*. 2007;**29**(4):380-8.
15. Nam Hee R, Jung Sook H, Dong Seok J, Jae Ryong K. Prevalence of Metallo- β -lactamases in *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Korean. *Korean J Clin Microbiol*. 2010;**13**(4):169-72.
16. Sadari H, Karimi Z, Owlia P, Bahar MA, Rad SMBA. Phenotypic Detection of Metallo-beta-lactamase Producing *Pseudomonas aeruginosa* Strains Isolated from Burned Patients. *Iran J Pathol*. 2008;**3**(1):20-4.
17. Sarkar B, Biswas D, Prasad R, Sharma JP. A clinicomicrobiological study on the importance of *Pseudomonas* in nosocomially infected ICU patients, with special reference to metallo beta-lactamase production. *Indian J Pathol Microbiol*. 2006;**49**(1):44-8.
18. Mihani F, Khosravi A. Isolation Of *Pseudomonas Aeruginosa* Strains Producing Metallo Beta Lactamases From Infections In Burned Patients And Identification Of Bla Imp And Bla Vim Genes By Pcr. *Iran J Med Microbiol*. 2007;**1**(1):23-31.
19. Rezaei H, Behzadian G, Najari S, Mostafaei M. Prevalence and detection of metallo- β -lactamase (MBL)-producing *Pseudomonas aeruginosa* strains from clinical isolates in Iran. *Annals of Microbiology*. 2007;**57**(2):293-5.
20. Yousefi S, Farajnia S, Nahaei MR, Akhi MT, Ghotaslou R, Soroush MH, et al. Detection of metallo-beta-lactamase-encoding genes among clinical isolates of *Pseudomonas aeruginosa* in north-west of Iran. *Diagn Microbiol Infect Dis*. 2010;**68**(3):322-5.